ECMO treatment on patients with respiratory failure because of COVID-19 and improvement of the clinical condition




ECMO treatment; Extracorporeal membrane oxygenation; Respiratory failure; COVID-19; Clinic efficacy.


Extracorporeal membrane oxygenation (ECMO) has been widely used in patients with severe respiratory failure caused by the new coronavirus (COVID-19). In those people, the pulmonary interstice is occupied by cells and inflammatory substances, which impairs gas exchange and causes hypoxemia. The ECMO treatment consists of boosting the blood of the person through a cannula to an artificial membrane capable of oxygenating it, which is then able to return to the body. The present study aimed to identify, on patients with respiratory failure due to COVID-19, whether the ECMO treatment compared to standard therapy provides improvements in the clinical condition. A systematic review of the literature was conducted in May 2021. The research was done in two databases: PubMed and BVS. From the resulting articles, 7 were selected because they fit the research criteria. From the analysis of the results, it was found that ECMO treatment is able to reduce the mortality of patients with severe respiratory failure when compared to other treatments. When used, this resource proved to be able to reduce the amount of inflammatory substances and the storm of cytokines, thus enabling improvement in the oxygen supply to vital organs and avoiding lung injuries resulting from mechanical damage. In addition, when used in conjunction with medications, it showed a reduction in inflammation. Therefore, it was perceived that ECMO is a good alternative to patients, but not when used alone. It is necessary to supplement treatment with medications that relieves the symptoms.


Abrams, P., Khoury, S., & Grant, A. (2007). Evidence-based medicine overview of the main steps for developing and grading guideline recommendations. Prog Urol, 17(3), 681-4.

Dequin, P. F., Heming, N., Meziani, F., Plantefève, G., Voiriot, G., Badié, J., François, B., et al. (2020). Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA, 324(13), 1-9.

Dioh, W., Chabane, M., Tourette, C., Azbekyan, A., Morelot-Panzini, C., Hajjar Lins, L. A. M., Nair, G. B., et al. (2020) Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. BMC Trials, 22(42).

Dos Santos, S. M., Costa, D. D. N., Santos, F. S., Pereira, R. S., & Santos, E. S. (2016). Cuidado ao paciente em ECMO (Extracorporeal Membrane Oxygenation): um desafio para a enfermagem. Sempesq, 4(4), 64-68.

Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda D., et al. (2020). Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA, 323(16), 1574-1581.

Haiduc, A. A., Alom, S., Melamed, N., & Harky, A. (2020). Role of extracorporeal membrane oxygenation in COVID‐19: a systematic review. Journal of Cardiac Surgery, 35(10), 2679-2687.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223), 497-506.

Jacobs, J. P., Stammers, A. H., Louis, J. S., Hayanga, J. W. A., Firstenberg, M. S., Mongero, L. B., Tesdahl E. A., et al. (2020). Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in COVID-19: experience with 32 patients. ASAIO J, 66, 722-730.

Kon, Z. N., Smith, D. E., Chang, S. H., Goldenberg, R. M., Angel, L. F., Carillo, J. A., Geraci, T. C., et al. (2020). Extracorporeal Membrane Oxygenation Support in Severe COVID-19. The Annals of Thoracic Surgery, 111(2), 537-543.

McInnes, M. D., Moher, D., Thombs, B. D., McGrath, T. A., Bossuyt, P. M., Clifford, T., & Willis, B. H. (2018). Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA, 319(4), 388-396.

Munshi, L., Walkey, A., Goligher, E., Pham, T., Uleryk, E. M., & Fan E. (2019). Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. Lancet Respir Med, 7, 163-172.

Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica. Santa Maria, RS: UFSM, NTE.

Petersen, M. W., Meyhoff, T. S., Helleberg, M., Kjær, M. B. N., Granholm, A., Hjortsø, C. J. S., Jensen, T. S., et al. (2020). Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis plan. Acta Anestesiológico Scand, 64(9), 1365-1375.

Ribeiro, A. P. R. (2020). ECMO A Terapia Que Salva Vidas: Revisão Sistemática. Revista Multidisciplinar e Psicologia, 54(14), 341-356.

Rilinger, J., Kern, W. V., Duerschmied, D., Supady, A., Bode, C., Staudacher, D. L., & Wengenmayer, T. (2020). A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials, 21, 470.

Roehrig, S., Hssain, A. A., Shallik, N. A. H., Elsaid, I. M. A., Mustafa, S. F., Smain, O. A. M., Molokhia, A. A., & Lance, M. D. (2020). Flow controlled ventilation in Acute Respiratory Distress Syndrome associated with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(1), 781.

Romano, T. G., Mendes, P. V., Park, M., & Costa, E. L. V. (2017). Extracorporeal respiratory support in adult patients. Jornal Brasileiro de Pneumologia [online], 43(1), 60-70.

Shaefi, S., Brenner, S. K., Gupta, S., O’Gara, B. P., Krajewski, M. L., Charytan, D. M., Chaudhry, S. et al. (2021). Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. Cuidados Intensivos Med, 47, 208-221.

Sousa, M. N. A., De Estrela, Y., De C. A., & Bezerra, A. L. D. (2020) Perfil epidemiológico de casos de coronavírus no Estado da Paraíba utilizando o Boletim Epidemiológico local. Informação em Pauta, 5(2), 91-106.

Verdejo, C., Vergara-Merino, L., Meza, N., Pérez-Bracchiglione, J., Carvajal-Juliá, N., Madrid, E., Rada. G., & Reyes, M, X, R. (2020). Macrolides for the treatment of COVID-19: a living, systematic review. Medwave, 20(11).

Wu, Z., & McGoogan J. M. (2020). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA, 323 (13), 1239-1242.



How to Cite

CARVALHO, V. M. L. M. de .; VIANA, L. B. de O. P. .; DINIZ, A. V. .; ALMEIDA, M. E. M. .; MELO, D. H. N. de .; MARTINS, D. M. .; FARIAS, T. B. C. de .; SOUSA, M. N. A. de . ECMO treatment on patients with respiratory failure because of COVID-19 and improvement of the clinical condition. Research, Society and Development, [S. l.], v. 10, n. 9, p. e2110917758, 2021. DOI: 10.33448/rsd-v10i9.17758. Disponível em: Acesso em: 20 sep. 2021.



Health Sciences